个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

A predictive model for therapy failure in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor therapy

| 认领 | 导出 | |

文献详情

资源类型：
Pubmed体系：
作者：
Zhang Xiaoshuai[1] * ; Liu Bingcheng[2] * ; Huang Jian[3] * ; Zhang Yanli Li[4] * ; Xu Na[5] * ; Gale Robert Peter[6] ; Li Weiming[7] ; Liu Xiaoli[5] ; Zhu Huanling[8] ; Pan Ling[8] ; Yang Yunfan[8] ; Lin Hai[9] ; Du Xin[10] ; Liang Rong[11] ; Chen Chunyan[12] ; Wang Xiaodong[13] ; Li Guohui[14] ; Liu Zhougang[15] ; Zhang Yanqing[16] ; Liu Zhenfang[17] ; Hu Jianda[18] ; Liu Chunshui[6] ; Li Fei[19] ; Yang Wei[15] ; Meng Li[20] ; Han Yanqiu[21] ; Lin Li'e[22] ; Zhao Zhenyu[22] ; Tu Chuanqing[23] ; Zheng Caifeng[23] ; Bai Yanliang[24] ; Zhou Zeping[25] ; Chen Suning[26] ; Qiu Huiying[26] ; Yang Lijie[14] ; Sun Xiuli[27] ; Sun Hui[28] ; Zhou Li[29] ; Liu Zelin[30] ; Wang Danyu[30] ; Guo Jianxin[31] ; Pang Liping[32] ; Zeng Qingshu[33] ; Suo Xiaohui[34] ; Zhang Weihua[35] ; Zheng Yuanjun[35] ; Huang Xiaojun[1,36,37] ; Jiang Qian[1,38] ;
机构： [1]Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China. [2]National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjing, China. [3]Department of Hematology, The First Affiliated Hospital of Zhejiang University, College of Medicine, Zhejiang University. Department of Hematology, The Fourth Affiliated Hospital of Zhejiang University, College of Medicine, Zhejiang University. Zhejiang Provincial Clinical Research Center for Hematological Disorders, Zhejiang, China. [4]Department of Hematology, Henan Cancer Hospital, The Affiliated Cancer Hospital of Zhengzhou University, Henan, China. [5]Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China. [6]Centre for Hematology, Department of Immunology and Inflammation, Imperial College London, London, UK. [7]Department of Hematology, Union hospital, Tongji Medical college, Huazhong University of Science and Technology, Wuhan, China. [8]Department of Hematology, Institute of Hematology, West China Hospital,Sichuan University, Sichuan, China. [9]Department of Hematology, the First Hospital of Jilin University, Jilin, China. [10]Department of Hematology, The Second People’s Hospital of Shenzhen, The First Affiliated Hospital of Shenzhen University, Shenzhen, China. [11]Department of Hematology, Xijing Hospital, Airforce Military Medical University, Xi’an, China. [12]Department of Hematology, Qilu Hospital of Shandong University, Jinan, China. [13]Department of Hematology, Sichuan Academy of Medical Sciences Sichuan Provincial People’s Hospital, Sichuan, China. [14]Department of Hematology, Xi’an international medical center hospital, Xi’an, China. [15]Department of Hematology, Shengjing Hospital of China Medical University, Shenyang, China. [16]Department of Hematology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China. [17]Department of Hematology, The First Affiliated Hospital of Guangxi Medical University, Guangxi, China. [18]Department of Hematology, The Second Affiliated Hospital of Fujian Medical University, Fujian, China. [19]Center of Hematology, The First Affiliated Hospital of Nanchang University, Nanchang, China. [20]Department of Hematology, Tongji Hospital of Tongji Medical College, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China. [21]Department of Hematology, The Affiliated Hospital of Inner Mongolia Medical University, Inner Mongolia, China. [22]Department of Hematology, Hainan General Hospital, Hainan, China. [23]Department of Hematology, Shenzhen Baoan Hospital, Shenzhen University Second Affiliated Hospital, Shenzhen, China. [24]Department of Hematology, Henan Provincial People’s Hospital [26]Zhengzhou University People’s Hospital, Henan, China. [25]Department of Hematology, the Second Hospital Affiliated to Kunming Medical University, Kunming, China. [26]National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Institute of Blood and Marrow Transplantation of Soochow University, Soochow, China. [27]Department of Hematology, The First Affiliated Hospital of Dalian Medical University, Dalian, China. [28]Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. [29]Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. [30]Department of Hematology, Huazhong University of Science and Technology Union Shenzhen Hospital, Nanshan Hospital, Shenzhen, China. [31]Department of Hematology, The Second Affiliated Hospital of Fujian Medical University, Fujian, China. [32]Department of Hematology, Peking University Shenzhen Hospital, Shenzhen, China. [33]Department of Hematology, The First Affiliated Hospital of Anhui Medical University, Anhui, China. [34]Department of Hematology, Handan Central Hospital, Handan, China. [35]Department of Hematology, First Hospital of Shanxi Medical University, Shanxi, China. [36]Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, China. [37]State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing, China. [38]Peking University People’s Hospital, Qingdao, China.
出处：
DOI： 10.1182/blood.2024024761
ISSN：

关键词： predictive model therapy failure chronic myeloid leukemia tyrosine kinase-inhibitor

摘要：
Although tyrosine kinase inhibitor (TKI) therapy has markedly improved the survival of people with chronic-phase chronic myeloid leukemia (CML), 20-30% of people still experienced therapy failure. Data from 1,955 consecutive subjects with chronic-phase CML diagnosed by the European LeukemiaNet (ELN) recommendations from 1 center receiving initial TKI imatinib or a second-generation (2G-) TKI therapy were interrogated to develop a clinical prediction model for TKI therapy failure. This model was subsequently validated in 3,454 subjects from 76 other centers. Using the predictive clinical co-variates associated with TKI therapy failure, we developed a model that stratified subjects into low-, intermediate- and high-risk subgroups with significantly different cumulative incidences of therapy failure (p < 0.001). There was good discrimination and calibration in the external validation dataset, and the performance was consistent with that of the training dataset. Our model had the better prediction discrimination than the Sokal and ELTS scores did, with the greater time-dependent area under the receiver-operator characteristic curve (AUROC) values and a better ability to re-defined the risk of therapy failure. Our model could help physicians estimate the likelihood of initial imatinib or 2G-TKI therapy failure in people with chronic-phase CML.Copyright © 2024 American Society of Hematology.

基金：
This study was funded by the National Nature Science Foundation of China (No. 81970140 and No. 82370161).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2024]版：
无
最新[2023]版：
大类 | 1 区 医学
小类 | 1 区 血液学
第一作者：
第一作者机构： [1]Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
共同第一作者：
通讯作者：
通讯机构： [1]Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China. [36]Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, China. [37]State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing, China. [38]Peking University People’s Hospital, Qingdao, China.
推荐引用方式(GB/T 7714)：
Zhang Xiaoshuai,Liu Bingcheng,Huang Jian,et al.A predictive model for therapy failure in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor therapy[J].Blood.2024,doi:10.1182/blood.2024024761.
APA：
Zhang Xiaoshuai,Liu Bingcheng,Huang Jian,Zhang Yanli Li,Xu Na...&Jiang Qian.(2024).A predictive model for therapy failure in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor therapy.Blood,,
MLA：
Zhang Xiaoshuai,et al."A predictive model for therapy failure in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor therapy".Blood .(2024)

相关文献

[1]Patient-reported outcomes in adults with tyrosine kinase inhibitor-resistant chronic myeloid leukemia receiving olverembatinib therapy [2]初诊慢性髓性白血病患者接受酪氨酸激酶抑制剂治疗现状分析：国内多中心、回顾性真实世界研究 [3]Four-year follow-up of patients with imatinib-resistant or intolerant chronic myeloid leukemia receiving dasatinib: efficacy and safety [4]Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial [5]Comparison of the Efficacy Among Nilotinib, Dasatinib, Flumatinib and Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients: A Real-World Multi-Center Retrospective Study [6]Flumatinib versus Imatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Phase 3, Randomized, Open-label, Multi-center FESTnd Study. [7]The Unique Spatial-Temporal Treatment Failure Patterns of Adjuvant Gefitinib Therapy: A Post Hoc Analysis of the ADJUVANT Trial (CTONG 1104) [8]Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial [9]Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial (vol 15, 113, 2022) [10]表皮生长因子受体酪氨酸激酶抑制剂ZD1839对鼻咽癌细胞系的作用

资源点击量：52808 今日访问量：2 总访问量：4561 更新日期：2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号